Correction: Tanguturi et al. Discovery of Novel Delta Opioid Receptor (DOR) Inverse Agonist and Irreversible (Non-Competitive) Antagonists. Molecules 2021, 26, 6693

Tanguturi, Parthasaradhireddy; Pathak, Vibha; Zhang, Sixue; Moukha-Chafiq, Omar; Augelli‐Szafran, Corinne E.; Streicher, John M.

doi:10.3390/molecules27061969

Molecules

2022

DOI: 10.3390/molecules27061969

|View full text |Cite

Correction: Tanguturi et al. Discovery of Novel Delta Opioid Receptor (DOR) Inverse Agonist and Irreversible (Non-Competitive) Antagonists. Molecules 2021, 26, 6693

Parthasaradhireddy Tanguturi

Vibha Pathak

Sixue Zhang

et al.

Abstract: There was an error in the original publication [...]

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

2024

Publication Types

Select...

Article3

Relationship

Self Cite1

Independent2

Authors

Journals

Cited by 3 publications

References 5 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

The role of opioid receptors in modulating Alzheimer’s Disease

Tanguturi

Streicher

2023

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a complex neurological disorder characterized by accumulation of amyloid plaques and neurofibrillary tangles. Long term investigation of AD pathogenesis suggests that β-site amyloid precursor protein [APP] cleaving enzyme 1 (BACE1) and γ-secretase enzymes promote the amyloidogenic pathway and produce toxic Aβ peptides that are predisposed to aggregate in the brain. Hence, the targeted inhibition of BACE1/γ-secretase expression and function is a promising approach for AD therapy. Several reports have suggested that the opioid family of G-protein coupled receptors modulate the etiology of AD progression. It has also been found that changes in the signaling pathways of opioid receptors increased the expression of BACE1 and γ-secretase, and is strongly correlated with abnormal production of Aβ and pathogenesis of AD. Thus, the opioid receptor family is a promising candidate for targeted drug development to treat AD. In this review, we outline the involvement and mechanisms of opioid receptor signaling modulation in Alzheimer’s Disease progression.

show abstract

The role of opioid receptors in modulating Alzheimer’s Disease

Tanguturi

Streicher

2023

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

show abstract

Opioids and Their Receptors: Present and Emerging Concepts in Opioid Drug Discovery II

Rijn

Spetea

2022

Molecules

View full text Add to dashboard Cite

show abstract

Buprenorphine as an innovation in the treatment of chronic pain

Fricová

2024

Neurol. pro Praxi

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Correction: Tanguturi et al. Discovery of Novel Delta Opioid Receptor (DOR) Inverse Agonist and Irreversible (Non-Competitive) Antagonists. Molecules 2021, 26, 6693

Abstract: There was an error in the original publication [...]

Cited by 3 publications

References 5 publications

The role of opioid receptors in modulating Alzheimer’s Disease

The role of opioid receptors in modulating Alzheimer’s Disease

Opioids and Their Receptors: Present and Emerging Concepts in Opioid Drug Discovery II

Buprenorphine as an innovation in the treatment of chronic pain

Contact Info

Product

Resources

About